Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone

Pharmacological Research

Volumn 65, Issue 3, 2012, Pages 312-319

  Hofman, Jakub ^a   Ahmadimoghaddam, Davoud ^a   Hahnova, Lenka ^a   Pavek, Petr ^a   Ceckova, Martina ^a   Staud, Frantisek ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

ABCG2; Breast cancer resistance protein; Cyclin dependent kinase inhibitors; Pharmacokinetics

Indexed keywords

BOHEMINE; BREAST CANCER RESISTANCE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; FUMITREMORGIN C; MITOXANTRONE; OLOMOUCINE; OLOMOUCINE II; PURVALANOL A; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARCINOMA IN SITU; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG INHIBITION; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL LINE; CYCLIN-DEPENDENT KINASES; CYTOSTATIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GLYBURIDE; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; PURINES;

EID: 84857060680     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.11.017     Document Type: Article

References (38)

1. H. Hochegger, S. Takeda, and T. Hunt Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol 9 2008 910 916
2. G.I. Shapiro Cyclin-dependent kinase pathways as targets for cancer treatment J Clin Oncol 24 2006 1770 1783 (Pubitemid 46628473)
3. V. Krystof, and S. Uldrijan Cyclin-dependent kinase inhibitors as anticancer drugs Curr Drug Targets 11 2010 291 302
4. F. Rizzolio, T. Tuccinardi, I. Caligiuri, C. Lucchetti, and A. Giordano CDK inhibitors: from the bench to clinical trials Curr Drug Targets 11 2010 279 290
5. J. Vesely, L. Havlicek, M. Strnad, J.J. Blow, A. Donella-Deana, and L. Pinna Inhibition of cyclin-dependent kinases by purine analogues Eur J Biochem 224 1994 771 786 (Pubitemid 24282865)
6. L. Meijer, and E. Raymond Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials Acc Chem Res 36 2003 417 425
7. F. Staud, and P. Pavek Breast cancer resistance protein (BCRP/ABCG2) Int J Biochem Cell Biol 37 2005 720 725 (Pubitemid 40202994)
8. J.P. Gillet, T. Efferth, and J. Remacle Chemotherapy-induced resistance by ATP-binding cassette transporter genes Biochim Biophys Acta 1775 2007 237 262 (Pubitemid 46899341)
9. J. Xu, H. Peng, and J.T. Zhang Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy Curr Med Chem 14 2007 689 701 (Pubitemid 46477721)
10. L.J. Hardwick, S. Velamakanni, and H.W. van Veen The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2) Br J Pharmacol 151 2007 163 174 (Pubitemid 46763043)
11. P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna, and J.W. Jonker Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine, and transport of cimetidine J Pharmacol Exp Ther 312 2005 144 152 (Pubitemid 40096463)
12. L. Cerveny, P. Pavek, J. Malakova, F. Staud, and Z. Fendrich Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents Epilepsia 47 2006 461 468 (Pubitemid 43351546)
13. L.H. Cygalova, J. Hofman, M. Ceckova, and F. Staud Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility J Pharmacol Exp Ther 331 2009 1118 1125
14. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
15. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 2006 621 681
16. C.W. Scharenberg, M.A. Harkey, and B. Torok-Storb The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors Blood 99 2002 507 512 (Pubitemid 34533085)
17. S.K. Rabindran, D.D. Ross, L.A. Doyle, W. Yang, and L.M. Greenberger Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein Cancer Res 60 2000 47 50 (Pubitemid 30058728)
18. C. Gedeon, J. Behravan, G. Koren, and M. Piquette-Miller Transport of glyburide by placental ABC transporters: implications in fetal drug exposure Placenta 27 2006 1096 1102 (Pubitemid 44400512)
19. T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, and D.D. Ross The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) J Cell Sci 113 Pt 11 2000 2011 2021 (Pubitemid 30386505)
20. M. Ceckova, A. Libra, P. Pavek, P. Nachtigal, M. Brabec, and R. Fuchs Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo Clin Exp Pharmacol Physiol 33 2006 58 65
21. G. Li, X. Chen, Q. Wang, Z. Xu, W. Zhang, and L. Ye The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance J Huazhong Univ Sci Technol Med Sci 27 2007 173 175
22. F. Staud, Z. Vackova, K. Pospechova, P. Pavek, M. Ceckova, and A. Libra Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line J Pharmacol Exp Ther 319 2006 53 62 (Pubitemid 44455110)
23. L.M. Schang, M.R. St Vincent, and J.J. Lacasse Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs Antivir Chem Chemother 17 2006 293 320 (Pubitemid 46043181)
24. J. Holcakova, P. Tomasec, J.J. Bugert, E.C. Wang, G.W. Wilkinson, and R. Hrstka The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties Antivir Chem Chemother 20 2010 133 142
25. I.T. Aldoss, T. Tashi, and A.K. Ganti Seliciclib in malignancies Expert Opin Investig Drugs 18 2009 1957 1965
26. Z. Rajnai, D. Mehn, E. Beery, A. Okyar, M. Jani, and G.K. Toth ABCB1 transports Seliciclib (R-Roscovitine), a cyclin-dependent kinase inhibitor Drug Metab Dispos 38 2010 2000 2006
27. C.J. Bachmeier, and D.W. Miller A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier Pharm Res 22 2005 113 121 (Pubitemid 40558153)
28. R. An, Y. Hagiya, A. Tamura, S. Li, H. Saito, and D. Tokushima Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro Pharm Res 26 2009 449 458
29. L. Gonzalez-Lobato, R. Real, J.G. Prieto, A.I. Alvarez, and G. Merino Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C Eur J Pharmacol 644 2010 41 48
30. Y. Xie, K. Xu, D.E. Linn, X. Yang, Z. Guo, and H. Shimelis The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells J Biol Chem 283 2008 3349 3356
31. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res 70 2010 440 446
32. M.V. Appleyard, M.A. O'Neill, K.E. Murray, F.E. Paulin, S.E. Bray, and N.M. Kernohan Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model Int J Cancer 124 2009 465 472
33. M.S. Abaza, A.M. Bahman, and R.J. Al-Attiyah Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells World J Gastroenterol 14 2008 5162 5175
34. H.M. Coley, C.F. Shotton, and H. Thomas Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines Anticancer Res 27 2007 273 278 (Pubitemid 46363342)
35. A.H. Schinkel, and J.W. Jonker Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview Adv Drug Deliv Rev 55 2003 3 29 (Pubitemid 36078452)
36. E. Crescenzi, G. Palumbo, and H.J. Brady Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy Clin Cancer Res 11 2005 8158 8171 (Pubitemid 41698760)
37. M. Federico, C.E. Symonds, L. Bagella, F. Rizzolio, D. Fanale, and A. Russo R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair Mol Cancer 9 2010 208
38. J.G. Pizarro, J. Folch, F. Junyent, E. Verdaguer, C. Auladell, and C. Beas-Zarate Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells Apoptosis 16 2011 536 550